Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia

Coronado Biosciences, Inc.

today announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for CNDO-109, a novel biologic that primes natural killer cells without the need for cytokines (IL-2), and is being studied for the treatment of patients with high risk acute myeloid leukemia in first complete remission. Results from a Phase I investigator-initiated clinical trial of CNDO-109 were presented at the 53rd American Society of Hematology Annual Meeting and Exposition on December 13, 2011. Although the primary endpoint of the Phase I clinical trial was safety, the results demonstrated that the majority of AML patients experienced a longer complete remission after receiving CNDO-109 activated NK cells than their previous complete remission.